Safety and Efficacy of Biologic Medications and Janus Kinase Inhibitors in Patients with Down Syndrome: A Retrospective Cohort Study

Clin Drug Investig. 2024 Mar;44(3):219-222. doi: 10.1007/s40261-024-01348-0. Epub 2024 Feb 19.

Authors

Linnea Westerkam¹, Lauren Pearson², Christopher Sayed³

Affiliations

¹ University of North Carolina School of Medicine, Chapel Hill, NC, USA. [email protected].
² University of North Carolina School of Medicine, Chapel Hill, NC, USA.
³ Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

PMID: 38372935
DOI: 10.1007/s40261-024-01348-0

No abstract available

Publication types

Letter

MeSH terms

Biological Products*
Down Syndrome* / drug therapy
Humans
Janus Kinase Inhibitors* / adverse effects
Protein Kinase Inhibitors / adverse effects
Retrospective Studies

Substances

Janus Kinase Inhibitors
Protein Kinase Inhibitors
Biological Products